The KIF21A Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 lung adenocarcinoma cell line, with targeted disruption of the KIF21A gene. This heterogeneous pool of knockout cells enables loss-of-function studies of this kinesin motor protein in a cancer-relevant model, bypassing clonal isolation. The polyclonal format retains biological variability suitable for pooled functional genomics and population-based assays.
A-549 cells, isolated from a 58-year-old Caucasian male with lung adenocarcinoma, are a standard model for non-small cell lung cancer. These transformed alveolar epithelial cells exhibit uncontrolled proliferation and aneuploidy, making them particularly apt for mitosis and chromosome segregation studies. Their well-characterized signaling pathways and genetic tractability facilitate the investigation of mitotic regulators like KIF21A.
KIF21A encodes a plus-end-directed kinesin motor protein critical for mitotic spindle assembly, chromosome alignment, and cell division. It is regulated by CDK1, PLK1, Aurora kinases A/B, and the transcription factor FOXM1, and functions within a mitotic network comprising AURKA, AURKB, PLK1, CDK1, Cyclin B, and NDC80. KIF21A directly interacts with microtubules, Aurora kinases, and CEP170 to promote microtubule polymerization and chromosome segregation fidelity. Disruption of KIF21A abrogates proper spindle formation and mitotic progression, leading to chromosome misalignment and genomic instability.
In A-549 lung adenocarcinoma cells, KIF21A knockout intensifies mitotic aberrations and genomic instability, providing a platform to test sensitivities to mitotic inhibitors such as Aurora kinase or PLK1 antagonists. Additionally, this model contributes to congenital fibrosis of the extraocular muscles type 1 (CFEOM1) research by allowing assessment of how KIF21A loss affects cellular processes relevant to neuronal development in induced differentiation contexts.
Applications include mitotic spindle regulation, cancer cell division research, and mitosis-targeted drug validation. Compatible assays encompass western blotting, RT?qPCR, tubulin immunofluorescence, flow cytometry for cell cycle, mitotic index scoring, Annexin V apoptosis, MTT viability, and time?lapse imaging. The polyclonal population supports high?throughput phenotypic screens and synthetic lethal interaction studies. For further information or technical support, please contact Ascent Research.
